Research Briefs
Laboratory and in-vitro research summaries | Pure Form LLC | www.pfpep.com
Updated September 2026 | Not medical advice. Not for human or veterinary use.
All products discussed are sold strictly for laboratory and in-vitro research use only. They are not intended for human or animal consumption, or for therapeutic, diagnostic, or clinical use. These briefs summarize published literature. They are not protocols.
BPC-157
BPC-157 Research Applications: What Preclinical Studies Have Examined
Explore the published research on BPC-157 (Body Protection Compound-157), a synthetic pentadecapeptide studied in laboratory models of tissue repair, angiogenesis, and cytoprotection.
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. In research settings it is frequently examined for its effects on soft-tissue models.
Key research areas examined in preclinical literature. Multiple rodent studies have investigated BPC-157 in models of tendon, ligament, and muscle injury. Reviews published in Cell and Tissue Research (2019) and Pharmaceuticals (2026) summarize findings of accelerated healing in transected Achilles tendon, quadriceps muscle, and medial collateral ligament models when the peptide is administered systemically or locally.
Researchers have also studied its influence on angiogenesis and blood-vessel recruitment around injury sites, as well as its interaction with the nitric oxide system in perforated gastrointestinal models (World Journal of Gastroenterology, 2018). Additional work has explored recovery of myotendinous junctions and counteraction of muscle atrophy after surgical detachment (Biomedicines, 2021; Pharmaceutics, 2025).
Spinal-cord injury models in rats have examined functional recovery metrics after BPC-157 administration (Journal of Orthopaedic Surgery and Research, 2019). Wound-healing studies, including burn and alkali-burn models, have reported earlier granulation tissue formation and collagen organization.
Research considerations. Virtually all published data remain preclinical, primarily rodent. No large-scale human clinical trials establishing safety or efficacy for any indication have been completed as of 2026. Mechanisms proposed in the literature include modulation of the FAK-paxillin pathway, VEGF upregulation, and cytoprotective signaling, but these require further independent verification.
Sources. PubMed IDs 30915550, 30622376, 31266512, and related reviews in Pharmaceuticals (2026) and Biomedicines.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
TB-500
TB-500 (Thymosin Beta-4 Fragment) Research: Tissue Repair and Cell Migration Studies
Review of published research on TB-500, the synthetic fragment of thymosin beta-4 studied for actin regulation, wound healing, and tissue regeneration models.
TB-500 is a synthetic peptide corresponding to the actin-binding domain of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide present in most human cells. Research interest centers on its role in cytoskeletal dynamics and cell migration.
Primary research focus areas. Foundational studies (Malinda et al., 1999 and subsequent work) demonstrated accelerated re-epithelialization and wound closure in rodent dermal models. Phase 2 human trials of full-length thymosin beta-4 (not the TB-500 fragment) have examined topical application in venous stasis ulcers and dry-eye models, showing improved healing metrics and reduced corneal staining in some cohorts.
Cardiac research has investigated Tβ4 for myocardial protection and angiogenesis after experimental infarction (Bock-Marquette et al. and later reviews). Additional preclinical work has explored effects on corneal repair, hair-follicle cycling, and neuroprotection in traumatic brain injury models.
A 2026 scoping review in Applied Sciences mapped 80 studies and found the strongest concentration of evidence in wound/skin, vascular/endothelial, and ocular categories, with more limited direct musculoskeletal data for the TB-500 fragment specifically.
Research notes. Most published clinical data involve full-length thymosin beta-4 rather than the shorter synthetic TB-500 fragment. Direct human evidence for injectable TB-500 remains limited. The peptide is studied for its ability to sequester G-actin and influence cell motility, but translation of these findings requires careful experimental design.
Sources. Malinda et al. (1999), Applied Sciences scoping review (2026), Phase 2 dry-eye data (Cornea, 2015), and cardiac regeneration literature.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
GHK-Cu
GHK-Cu Copper Peptide Research: Collagen, Extracellular Matrix, and Skin Models
Scientific overview of GHK-Cu (glycyl-L-histidyl-L-lysine-copper) research on collagen synthesis, wound remodeling, and gene expression in dermal fibroblasts.
GHK-Cu is a naturally occurring tripeptide-copper complex first isolated from human plasma. Research has focused on its ability to modulate extracellular-matrix components.
Documented research findings. In vitro studies with human dermal fibroblasts show GHK-Cu increases production of collagen types I, III, and IV, elastin, and glycosaminoglycans at nanomolar concentrations (Maquart, Borel, and subsequent work). It also modulates matrix metalloproteinases (MMPs) and their inhibitors (TIMPs), influencing tissue remodeling.
Ex-vivo and clinical topical studies have reported improvements in skin thickness, wrinkle volume, and collagen density after application of GHK-Cu formulations. A randomized trial comparing GHK-Cu to vitamin C and retinoic acid found higher rates of increased collagen production in biopsy samples. Synergistic effects with hyaluronic acid on collagen IV upregulation have been observed in recent cell and ex-vivo tests (Jiang et al., 2023).
Gene-expression analyses indicate GHK-Cu can reset patterns associated with tissue repair and reduce pro-inflammatory signaling (TGF-β, IL-6) in certain models.
Research context. While topical cosmetic use has a longer history, injectable or systemic research applications remain preclinical or early-stage. Delivery methods (nano-carriers, microneedles) continue to be explored to improve bioavailability in experimental settings.
Sources. Pickart reviews, Maquart et al., Jiang et al. (Journal of Cosmetic Dermatology, 2023), and systematic reviews in aesthetic dermatology (2026).
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
CJC-1295 (No DAC)
CJC-1295 No DAC (Modified GRF 1-29) Research: Pulsatile Growth Hormone Studies
Overview of research on CJC-1295 without DAC, a short-acting GHRH analog studied for pulsatile growth-hormone release in laboratory models.
CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH). Four amino-acid substitutions increase resistance to enzymatic degradation while preserving a short half-life of approximately 30 minutes.
Research focus. Unlike the long-acting DAC version (which binds albumin and produces sustained elevation lasting days), the no-DAC form generates discrete, pulsatile GH release that more closely resembles endogenous GHRH signaling. This pharmacokinetic profile makes it a useful tool for studies examining physiological pulse patterns.
Human pharmacokinetic data primarily exist for the DAC form (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006), which demonstrated multi-day GH and IGF-1 elevation. The no-DAC variant is more commonly studied in combination protocols with growth-hormone secretagogues such as Ipamorelin to investigate synergistic receptor pathways (GHRH receptor + GHS-R1a).
Preclinical and limited clinical observations note transient rises in GH followed by return to baseline, supporting research into pulsatile versus continuous stimulation of the GH/IGF-1 axis.
Laboratory considerations. Researchers select the no-DAC form when the experimental goal is short-duration receptor activation rather than prolonged exposure. Proper storage, reconstitution, and handling protocols are essential for reproducible results.
Sources. Teichman et al. (2006), comparative pharmacokinetic reviews, and GHRH analog literature distinguishing DAC vs no-DAC variants.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
Ipamorelin
Ipamorelin Research Applications: Growth Hormone Secretagogue Studies in Laboratory Models
Explore published research on Ipamorelin, a selective growth hormone secretagogue studied for GH release and related metabolic pathways.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed as a selective growth hormone secretagogue. It acts primarily at the ghrelin receptor (GHS-R1a).
Key research findings. Early pharmacological characterization showed Ipamorelin releases GH from rat pituitary cells with potency comparable to GHRP-6 while displaying higher selectivity (Hansen et al., European Journal of Endocrinology, 1998). In human volunteer pharmacokinetic-pharmacodynamic studies, intravenous Ipamorelin produced a single episode of GH release peaking around 0.67 hours, with a short terminal half-life of approximately 2 hours (Gobburu et al., Pharmaceutical Research, 1999).
Rodent studies have examined its effects on nitrogen balance during steroid-induced catabolism, longitudinal bone growth, and somatotroph cell responses after chronic administration. These experiments documented GH-related metabolic effects and dose-dependent influences on growth parameters in young female rats.
Researchers often pair Ipamorelin with short-acting GHRH analogs (such as CJC-1295 No DAC) in laboratory protocols to investigate complementary receptor pathways (GHS-R1a + GHRH receptor).
Research notes. Most human data focus on acute GH stimulation rather than long-term outcome endpoints. No large Phase 3 trials for body-composition or recovery indications appear in the published literature as of 2026.
Sources. Hansen et al. (1998), Gobburu et al. (1999), Johansen et al. (Growth Hormone & IGF Research), and related PubMed entries on GH secretagogues.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
Tesamorelin
Tesamorelin Research: Visceral Adipose Tissue and Metabolic Studies
Review of clinical and laboratory research on Tesamorelin, a GHRH analog examined for visceral fat reduction and related endpoints.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH 1-44). It is the active ingredient in the FDA-approved product Egrifta for a specific indication.
Documented research. Two multicenter Phase 3 randomized, placebo-controlled trials in HIV-infected adults with excess abdominal fat demonstrated statistically significant reductions in visceral adipose tissue (VAT) measured by CT scan. In the pivotal study of 412 patients, daily 2 mg subcutaneous Tesamorelin reduced VAT by 15.2% over 26 weeks versus a 5.0% increase with placebo (Falutz et al., New England Journal of Medicine, 2007). Pooled analyses of more than 800 participants confirmed VAT reductions of approximately 15% with concurrent improvements in triglycerides and certain lipid ratios, while subcutaneous fat remained largely unchanged.
A subsequent randomized trial also reported modest reductions in liver fat content alongside VAT decreases (JAMA, 2014). Extension data showed that continued treatment maintained VAT reductions for up to 52 weeks, with rapid return toward baseline upon discontinuation.
Research context. Tesamorelin has an approved clinical indication limited to HIV-associated lipodystrophy. Broader laboratory investigations continue to examine GHRH-pathway effects on body composition and metabolic markers under controlled experimental conditions. Research materials containing Tesamorelin are for in-vitro and laboratory use only and are not intended for any off-label or non-research application.
Sources. Falutz et al. (NEJM 2007), pooled Phase 3 analyses (Journal of Clinical Endocrinology & Metabolism 2010), JAMA liver-fat study (2014), and FDA labeling for Egrifta.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
MOTS-c
MOTS-c Mitochondrial Peptide Research: Metabolic Homeostasis and AMPK Pathway Studies
Scientific overview of MOTS-c, a mitochondria-encoded peptide studied for insulin sensitivity, energy metabolism, and related cellular pathways.
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It was first characterized in 2015.
Primary research areas. Foundational work in Cell Metabolism demonstrated that MOTS-c regulates insulin sensitivity and metabolic homeostasis in mice. Treatment prevented age-dependent and high-fat-diet-induced insulin resistance and reduced diet-induced obesity via AMPK activation and inhibition of the folate-purine pathway in skeletal muscle (Lee et al., 2015).
Subsequent preclinical studies have examined effects on glucose clearance, mitochondrial respiration in diabetic heart models, non-alcoholic steatohepatitis progression, physical endurance in aged mice, and inflammatory responses in various tissue models. Circulating MOTS-c levels have been measured in human observational cohorts related to obesity, type 2 diabetes, and exercise.
Research notes. As of 2026, human efficacy data remain limited; most mechanistic and outcome findings derive from animal and cell models. Ongoing interest focuses on its dual role as a biomarker and experimental metabolic regulator.
Sources. Lee et al. (Cell Metabolism 2015), subsequent reviews in Frontiers in Endocrinology and Journal of Translational Medicine, and related PubMed literature on mitochondrial-derived peptides.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
PT-141
PT-141 (Bremelanotide) Research: Melanocortin Receptor and Sexual Function Studies
Overview of research on PT-141 (bremelanotide), a melanocortin receptor agonist examined in central pathways related to sexual desire and arousal.
PT-141 (bremelanotide) is a cyclic heptapeptide analog of α-melanocyte-stimulating hormone. It activates several melanocortin receptors, with highest affinity at MC4R.
Key research findings. Preclinical work established that MC4R agonism in the medial preoptic area influences appetitive sexual behaviors in rodent models. Human Phase 3 RECONNECT trials in premenopausal women with hypoactive sexual desire disorder (HSDD) demonstrated statistically significant increases in sexual desire scores and reductions in related distress compared with placebo after on-demand subcutaneous administration (Kingsberg et al., Obstetrics & Gynecology 2019). These data supported FDA approval of the branded product Vyleesi for that specific indication.
Additional studies have explored brain processing of erotic stimuli under MC4R agonism using functional neuroimaging, showing changes in activity and connectivity in regions associated with sexual imagery and motivation.
Research context. PT-141 research continues to examine melanocortin signaling in both male and female models. The approved clinical use is narrow; laboratory investigations focus on receptor pharmacology and central pathways. Research-grade PT-141 is supplied solely for in-vitro and laboratory purposes.
Sources. RECONNECT Phase 3 publications, receptor binding studies, and neurobiology reviews in CNS Spectrums and related journals.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
Semax
Semax Peptide Research: BDNF Upregulation and Cognitive Pathway Studies
Review of laboratory research on Semax, an ACTH(4-10) analog studied for effects on brain-derived neurotrophic factor and learning models.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment with a stabilizing Pro-Gly-Pro extension.
Documented research. Intranasal administration of Semax (50 µg/kg) in rats produced a rapid increase in hippocampal BDNF protein (approximately 1.4-fold), TrkB phosphorylation, and BDNF mRNA levels (up to 3-fold for exon III) within hours (Dolotov et al., Brain Research 2006). Parallel studies reported elevated BDNF in the basal forebrain and increased expression of both BDNF and NGF genes in hippocampus and frontal cortex.
Behavioral experiments showed improved performance in conditioned avoidance tasks. Additional work has examined neuroprotective effects in models of cerebral ischemia and modulation of monoamine systems. Limited human neuroimaging studies have explored effects on default-mode network activity.
Research notes. The majority of peer-reviewed data originate from Russian research groups. Western replication and large controlled trials remain limited as of 2026.
Sources. Dolotov et al. (Brain Research 2006 and Journal of Neurochemistry), gene-expression time-course studies, and related PubMed entries on ACTH analogs.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.
Selank
Selank Peptide Research: Anxiolytic and GABA-System Studies
Scientific summary of Selank, a tuftsin-derived heptapeptide examined in anxiety and stress-response models.
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built on the tuftsin core with a stabilizing C-terminal extension. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.
Primary research focus. Russian clinical studies in patients with generalized anxiety disorder and related conditions reported anxiolytic effects comparable in magnitude to certain benzodiazepines in head-to-head comparisons, without the same degree of sedation in the reported cohorts (Zozulia et al., 2008 and follow-on trials). Mechanism research indicates modulation of GABAergic gene expression, effects on enkephalinase activity, and influences on cytokine balance.
Preclinical work has demonstrated anxiolytic and antistress activity in rodent models of chronic mild stress and immobilization stress, with concurrent reductions in corticosterone in some experiments. Dual neuro-immune activity linked to its tuftsin origin has also been documented in human blood-cell studies.
Research context. Selank is registered in Russia for anxiety-related indications. Independent Western randomized controlled trials remain sparse. Laboratory interest centers on non-benzodiazepine GABA-system modulation and stress-resilience pathways.
Sources. Zozulia et al. (2008), gene-expression studies (Volkova et al., Filatova et al.), and Russian clinical literature on tuftsin analogs.
Important: This compound is sold strictly for laboratory research purposes only. It is not approved by the FDA for human or veterinary use.